Definium Therapeutics Inc (DFTX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access DFTX Annual Balance Sheets →
From Definium Therapeutics Inc through Jun 30 2025, shifts in Jun 30 2026's assets and liabilities provide insight into the company's capital structure and financial stability.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent655.27
Short-term Investments, Total428.61
Cash & Short-term Investments1,083.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current8.22
Total Current Assets1,092.10
Goodwill net19.92
Long-term investments0.00
Other Assets, Noncurrent0.88
Total Assets1,112.90
Liabilities
Accounts Payable, Current AC6.97
Accrued Liabilities, Current AC37.22
Other Liabilities, Current113.02
Total Current Liabilities157.20
Long-term debt36.47
Total Long-term Debt36.47
Other liabilities, Noncurrent0.55
Financing Warrants Liability49.47
Total Liabilities194.22
Stockholders' Equity
Additional Paid In Capital Common Stock1,737.02
Retained Earnings / Accumulated Deficit-818.76
Accumulated Other Comprehensive Income0.42
Other Equity0.42
Common Stockholder's Equity918.68
Total Stockholder's Equity918.68
Liabilities & Stockholder's Equity1,112.90
4 historic quarters locked

Sign in to unlock the full Definium Therapeutics Inc balance sheet history.

About Definium Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-338066

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.